Upgraded Cobas TaqMan version 2: hidden consequences at cohort level

Taylor, N, Grabmeier-Pfistershammer, K, Oberkofler, H, Egle, A, Rieger, A, Ledergerber, B J INT AIDS SOC. 2012, 15: 109-109.

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

dxxxAmore, F, Leppa, S, da Silva, MC, Relander, T, Brown, PD, Weidmann, E, Lauritzsen, GF, Pezzutto, A, Van Hoof, A, van Gelder, M, Doorduijn, JK, Wu, KL, Kluin-Nelemans, JC, Lugtenburg, PJ, Jankovska, M, Merup, M, Fagerli, UM, Walewski, J, Hagberg, H, Mariz, JM, Hansen, PB, Nosslinger, T, Janssens, A, Brandefors, L, Demuynck, H, Schaafsma, MR, Christiansen, I, Salek, D, Jyrkkio, S, Prochazka, V, Zijlstra, J, Bohmer, L, Greil, R, Stevens, W, Fijnheer, R, Kooy, MV, Grube, M, Hopfinger, G, Van den Neste, E, Jantunen, E, Trumper, L, Wulf, G, Altmann, B, Ziepert, M, Loeffler, M, Toldbod, H BLOOD. 2012, 120(21):

RITUXIMAB PLUS SUBCUTANEOUS CLADRIBINE IN PATIENTS WITH EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF THE MUCOSA ASSOCIATED TISSUE (MALT-LYMPHOMA): A PHASE II STUDY BY THE AGMT (ARBEITSGEMEINSCHAFT MEDIKAMENTOSE TUMORTHERAPIE)

Troch, M, Kiesewetter, B, Willenbacher, W, Willenbacher, E, Zebisch, A, Linkesch, W, Fridrik, MA, Mullauer, L, Greil, R, Raderer, M ANN ONCOL. 2012, 23: 352-352.

IMPACT OF NUMBER OF PREVIOUS TREATMENT LINES AND PRE-TREATMENT WITH BORTEZOMIB OR LENALIDOMIDE ON EFFICACY OF BORTEZOMIB-BENDAMUSTINE-DEXAMETHASONE (BBD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)

Ludwig, H, Kasparu, H, Leitgeb, C, Greil, R, Rauch, E, Linkesch, W, Zojer, N, Pour, L, Fillitz, M, Adam, Z ANN ONCOL. 2012, 23: 348-349.

Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).

Arnold, D, Andre, T, Bennouna, J, Sastre, J, Osterlund, PJ, Greil, R, Van Cutsem, E, Von Moos, R, Reyes-Rivera, I, Bendahmane, B, Kubicka, S J CLIN ONCOL. 2012, 30(18):

BIOMARKER (BM) RESULTS FROM THE PHASE III AVEREL TRIAL OF 1ST-LINE BEVACIZUMAB (BV), TRASTUZUMAB (H) plus DOCETAXEL (T) FOR HER2-POSITIVE LOCALLY RECURRENT/METASTATIC BREAST CANCER (LR/MBC)

Gianni, L, Chan, A, Mansutti, M, Pivot, X, Greil, R, Provencher, L, Prot, S, Moore, N, Scherer, SJ, Pallaud, C ANN ONCOL. 2012, 23: 531-532.

Influence of the American ODAC statement upon Austrian prescription practice of bevacizumab in metastatic breast cancer

Preusser, M, Fulop, G, Berghoff, AS, Heinzl, H, Steger, GG, Greil, R, Zielinski, CC, Bartsch, R ONKOLOGIE. 2012, 35: 66-66. und erschienen unter: Oncologist. 2012,17(7):e13-7. doi: 10.1634/theoncologist.2012-0115. Epub 2012 Jun 27.

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: results of a randomised phase III intergroup study initiated by the AIO and AGMT (ML18147)

Greil, R, Arnold, D, Hegewisch-Becker, S, Freier, W, Steffens, CC, Bertram, M, Schlichting, C, Andel, J, Taylor, M, Makrutzki, M, Kubicka, S ONKOLOGIE. 2012, 35: 254-254.

Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.

Valent P, Gastl G, Geissler K, Greil R, Hantschel O, Lang A, Linkesch W, Lion T, Petzer AL, Pittermann E, Pleyer L, Thaler J, Wolf D. Crit Rev Oncol Hematol. 2012 Jun,82(3):370-7. doi: 10.1016/j.critrevonc.2011.08.002. Epub 2011 Sep 7.

First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.

Köhne CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E, Gamelin E, Decosta L, Karthaus M. J Cancer Res Clin Oncol. 2012 Jan,138(1):65-72. doi: 10.1007/s00432-011-1061-6. Epub 2011 Sep 30.